Sangamo BioSciences | SGMO - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
Alaunos Therapeutics USD -1.13M 1.11M 2024-09
Alnylam Pharmaceuticals USD 829.31M 219.56M 2025-12
Amgen USD 6.48B 307M 2025-09
Bayer EUR 5.35B 1.02B 2025-09
BioCryst Pharmaceuticals USD 153.05M 4.16M 2025-12
Biogen USD 1.65B 34.6M 2025-12
BioMarin Pharmaceutical USD 713.01M 81.81M 2025-12
Cipla INR 41.64B 6.31B 2025-12
Clal Biotechnology ILS -857K 1.42M 2022-06
Compugen USD 63.8M 63.56M 2025-12
CSL USD 4.46B 2.71B 2025-12
Gilead Sciences USD 6.31B 106M 2025-12
GlaxoSmithKline GBP 6.18B 106M 2025-12
Grifols EUR 766.49M 39.74M 2024-12
Ionis Pharmaceuticals USD 195M 40M 2025-12
J&J USD 16.6B 118M 2025-12
Karyopharm Therapeutics USD -30.78M 1.29M 2024-12
Merck USD 13.42B 431M 2025-09
Novartis USD 10.25B 570M 2025-12
Omeros USD -33.16M 18.52M 2024-06
Pfizer USD 3.54B 7.61B 2025-09
Roche Holding CHF 22.09B 10.04B 2025-12
Sangamo BioSciences -2.39M 1.09M 2024-06
Sanofi EUR 8.45B 1.31B 2025-12
Sarepta Therapeutics USD 43.55M 204.36M 2025-12
Tectonic Therapeutic USD 0 0 2025-03
Ultragenyx Pharmaceutical USD 178M 46.06M 2025-12
Vertex Pharmaceuticals USD 2.72B 62.4M 2025-12